Tablets of 500 mg № 20 (10×2) in blisters, № 20 in containers, solution for infusions of 5% in 100 ml in bottles, 100 ml in containers, 2 ml or 4 ml in disposable containers № 10, powder for oral administration .
1 tablet contains aminocaproic acid 500 mg
Store at a temperature from 0 to + 20 ° С in a dark place. Shelf life – 3 years.
Aminocaproic acid has antifibrinolytic, hemostatic effect in bleeding, which is caused by increased fibrinolysis. It blocks not only plasminogen activators and plasmin, but also partially kinins. In addition, it contributes to the stabilization of fibrin, its deposition in the bloodstream, contributes to the aggregation of platelets and red blood cells. In addition to antifibrinolytic action, it has anti-allergic activity, inhibits the formation of antibodies, increases the antitoxic function of the liver.
Indications for use: surgery and various pathological conditions with increased fibrinolytic activity of the blood and tissues: surgery on the brain, lungs, heart, vessels, thyroid, pancreas, prostate glands, with premature detachment of the placenta, long stay in the uterus of a dead fetus, uterine bleeding abortion acute pancreatitis, liver disease, hypoplastic anemia, nasal, gastrointestinal bleeding, bladder bleeding and
Inside appoint 100 mg / kg every 4 hours, dissolving the powder in sweet water or drinking it. Daily dose – 10-15 g. With acute hypofibrinogenemia, intravenous drip is administered to 100 ml of a 5% solution, and if necessary, repeat infusion at intervals of 4 hours.
In case of overdose, hypercoagulation, increased thrombosis are possible.
Aminocaproic acid is contraindicated for women during pregnancy. If necessary, the use of the drug during lactation should stop breastfeeding for this period.
When using aminocaproic acid, dizziness, nausea, diarrhea, inflammation of the upper respiratory tract mucosa, skin rash, headache, orthostatic hypotension, seizures, rhabdomyolysis, myoglobinuria, acute renal failure, subendocardial hemorrhage are possible.
Aminocaproic acid is contraindicated in case of hypersensitivity to the drug; tendency to thrombosis and thromboembolic diseases, coagulopathy due to diffuse intravascular coagulation of blood, which is not accompanied by a sharp activation of fibrinolysis, kidney disease with impaired function, impaired cerebral circulation, severe ischemic heart disease, hematuria, during pregnancy and lactation, during the birth of the family.
When administering aminocaproic acid, it is necessary to monitor the fibrinolytic activity of the blood and the content of fibrinogen, when administered intravenously, a coagulogram is examined.
The drug is not used to prevent increased blood loss during childbirth due to the possible development of thromboembolic complications.
Aminocaproic acid reduces the effect of anticoagulants, antiplatelet agents.
It is not recommended to drink alcohol while using the drug Aminocaproic acid.
Below are the drugs with the same ATC code level 3 or 4, or the same pharmacotherapeutic group. Before replacing the drug with an analogue, you should consult with your doctor!
- B: Means affecting the blood system and hematopoiesis
- B02: Antihemorrhagic drugs
- B02A: Fibrinolysis Inhibitors
- B02AA: Amino Acids
- Pamba: price, instruction
- Tranexam: price, instruction
- Trenax: price, instruction
Instructions for use, composition, side effects and other detailed information on this page for ease of perception is given in the free translation of the official manufacturer’s instructions. This material is for reference only. We do not manufacture or sell drugs. Remember: the need to use the drug, methods and doses are determined only by your doctor. Self-medication can be dangerous to your health!